The effects of obesity-associated insulin resistance on mRNA expression of peroxisome proliferator-activated receptor-γ target genes, in dogs

British Journal of Nutrition

Volumn 98, Issue 3, 2007, Pages 497-503

  Gayet, Constance ^a   Leray, Veronique ^a   Saito, Masayuki ^b   Siliart, Brigitte ^a   Nguyen, Patrick ^a  

^a LUNAM UNIVERSITÉ   (France)

^b HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Insulin resistance; mRNA; Obesity; Peroxisome proliferator activated receptor

Indexed keywords

ADIPONECTIN; GLUCOSE; GLUCOSE TRANSPORTER 4; INSULIN; LEPTIN; LIPID; LIPOPROTEIN LIPASE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DOG; FEEDING BEHAVIOR; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GLUCOSE METABOLISM; HORMONE BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; LEAN BODY WEIGHT; LIPID METABOLISM; NONHUMAN; OBESITY; PATHOGENESIS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SKELETAL MUSCLE;

ADIPONECTIN; ANIMALS; BLOOD GLUCOSE; DOGS; GENE EXPRESSION; GLUCOSE TRANSPORTER TYPE 4; INSULIN; INSULIN RESISTANCE; INTRA-ABDOMINAL FAT; LEPTIN; LIPOPROTEIN LIPASE; MUSCLE, SKELETAL; OBESITY; PPAR GAMMA; RNA, MESSENGER; TRIGLYCERIDES; TUMOR NECROSIS FACTOR-ALPHA; WEIGHT GAIN;

ANIMALIA; CANIS FAMILIARIS;

EID: 34548043023     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S000711450772514X     Document Type: Article

References (42)

1. Okuno A, Tamemoto H, Tobe Y, et al. (1998) Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 101, 1354-1361.
2. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, Heyman RA, Briggs M, Deeb S, Staels B & Auwerx J (1996) PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J 15, 5336-5348.
3. Cohen B, Novick D & Rubinstein M (1996) Modulation of insulin activities by leptin. Science 274, 1185-1188.
4. Miles PD, Romeo OM, Higo K, Cohen A, Rafaat K & Olefsky JM (1997) TNF-alpha-induced insulin resistance in vivo and its prevention by troglitazone. Diabetes 46, 1678-1683.
5. Maeda N, Takahashi M, Funahashi T, et al. (2001) PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50, 2094-2099.
6. Yamauchi T, Kamon J, Wald H, et al. (2001) The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7, 941-946.
7. Dana SL, Hoener PA, Bilakovics JM, Crombie DL, Ogilvie KM, Kauffman RF, Mukherjee R & Paterniti JR Jr (2001) Peroxisome proliferator-activated receptor subtype-specific regulation of hepatic and peripheral gene expression in the Zucker diabetic fatty rat. Metabolism 50 963-971.
8. Wu Z, Xie Y, Morrison RF, Bucher NL & Farmer SR (1998) PPARgamma induces the insulin-dependent glucose transporter GLUT4 in the absence of C/EBPalpha during the conversion of 3T3 fibroblasts into adipocytes. J Clin Invest 101, 22-32.
9. Park KS, Ciaraldi TP, Abrams-Carter L, Mudaliar S, Nikoulina SE & Henry RR (1997) PPAR-gamma gene expression is elevated in skeletal muscle of obese and type II diabetic subjects. Diabetes 46, 1230-1234.
10. Rieusset J, Andreelli F, Auboeuf D, Roques M, Vallier P, Riou JP, Auwerx J, Laville M & Vidal H (1999) Insulin acutely regulates the expression of the peroxisome proliferator-activated receptor-gamma in human adipocytes. Diabetes 48, 699-705.
11. Vidal-Puig AJ, Considine RV, Jimenez-Linan K Werman A, Pories WJ, Caro JF & Flier JS (1997) Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest 99, 2416-2422.
12. Barroso I, Gurnell M, Crowley VE, et al. (1999) Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402, 880-883.
13. Bergman RN, Van Citters GW, Mittelman SD, Den MK Hamilton-Wossler M, Kim SP & Ellmerer M (2001) Central role of the adipocyte in the metabolic syndrome. J Investig Med 49, 119-126.
14. Kirkness EF, Bafna V, Halpern AL, et al. (2003) The dog genome: survey sequencing and comparative analysis. Science 301, 1898-1903.
15. Bailhache E, Ouguerram K, Gayet C, Krempf M, Siliart B, Magof T & Nguyen P (2003) An insulin-resistant hypertriglyceridaemic normotensive obese dog model: Assessment of insulin resistance by the euglycaemic hyperinsulinaemic clamp in combination with the stable isotope technique. J Anim Physiol Anim Nutr 87, 86-95.
16. Iwase M, Kimura K, Komagome R, Sasaki N, Ishioka K, Honjoh T & Saito M (2000) Sandwich enzyme-linked immunosorbent assay of canine leptin. J Vet Med Sci 62, 207-209.
17. -ΔΔCT method. Methods 25, 402-408.
18. Young PW, Cawthorne MA, Coyle PJ, Holder JC, Holman GD, Kozka IJ, Kirkham DM, Lister CA & Smith SA (1995) Repeat treatment of obese mice with BRL 49653, a new potent insulin sensitozer, enhances insulin action in white adipocytes. Association with increased insulin binding and cell-surface GLUT4 as measured by photoaffinity labelling. Diabetes 44, 1087-1092.
19. Zhang B, Berger J, Zhou G, Elbrecht A, Biswas S, White-Carrington S, Szalkowski D & Moller DE (1996) Insulin- and mitogen-activated protein kinase-mediated phosphorylation and activation of peroxisome proliferator-activated receptor gamma. J Biol Chem 271, 31771-31774.
20. Hu E, Kim JB, Sarraf P & Spiegelman BM (1996) Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamina. Science 274, 2100-2103.
21. Pamies-Andreu E, Fiksen-Olsen M, Rizza RA & Romero JC (1995) High-fructose feeding elicits insulin resistance without hypertension in normal mongrel dogs. Am J Hypertens 8, 732-738.
22. Rocchini AP, Marker P & Cervenka T (1997) Time course of insulin resistance associated with feeding dogs a high-fat diet. Am J Physiol 272 (1 Pt 1), E147-E154.
23. Kim SP, Ellmerer M, Van Citters GW & Bergman RN (2003) Primacy of hepatic insulin resistance in the development of the metabolic syndrome induced by an isocaloric moderate-fat diet in the dog. Diabetes 52, 2453-2460.
24. McAuley K & Mann J (2006) Thematic review series: Patient-oriented research. Nutritional determinants of insulin resistance. J Lipid Res 47, 1668-1676.
25. Peterson XF, Befroy D, Dufour S, Dziura J, Ariayan C, Rothman DL, DiPietro L, Cline GW & Shulman GI (2003) Mitochondrial dysfunction in the elderly: Possible role in insulin resistance. Science 300 1140-1142.
26. Mingrone G, Rosa G, Di Rocco P, Manco M, Capristo E, Castagneto M, Vettor R, Gasbarrini G & Greco AV (2002) Skeletal muscle triglycerides lowering is associated with net improvement of insulin sensitivity, TNF-alpha reduction and GLUT4 expression enhanceident. Int J Obes Relat Metab Disord 26, 1165-1172.
27. Kageyama H, Hirano T, Okada K, Ebara T, Kageyama A, Murakami T, Shioda S & Adachi M (2003) Lipoprotein lipase mRNA in white adipose tissue but not in skeletal muscle is increased by pioglitazone through PPAR-gamma. Biochem Biophys Res Commun 305, 22-27.
28. Montague CT, Prins JB, Sanders L, Zhang J, Sewter CP, Digby J, Byrne CD & O'Rahilly S (1998) Depot-related gene expression in human subcutaneous and omental adipocytes. Diabetes 47, 1394-1391.
29. Fujioka S, Matsuzawa Y, Tokunaga K & Tarui S (1987) Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism 36, 54-59.
30. Kelley DE, Thaete FL, Troost F, Huwe T & Goodpagter BH (2000) Subdivisions of subcutaneous abdominal adipose tissue and insulin resistance. Am J Physiol 278, E941-E948.
31. Norris AW, Chen L, Fisher SJ, et al. (2003) Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J Clin Invest 112 608-618.
32. Zierath JR, Ryder JW, Doebber T, et al. (1998). Role of skeletal muscle in thiazolidinedione insulin sensitizer (PPARgamma agonist) action. Endocrinology 139, 5034-5041.
33. Eckel RH (1989) Lipoprotein lipase. A multifunctional enzyme relevant to common metabolic diseases. N Engl J Med 320, 1060-1068. [Erratum in: N Engl J Med (1990), 322, 477.]
34. Bailhache E, Nguyen P, Krempf M, Siliart B, Magot T, & Ouguerram K (2003) Lipoproteins abnormalities in obese insulin-resistant dogs. Metabolism 52, 559-564.
35. Preiss-Landl K, Zimmermann R, Hammerle G & Zechner R (2001) Lipoprotein lipase: The regulation of tissue specific expression and its role in lipid and energy metabolism. Curr Opin Lipidol 13, 471-481.
36. Boucher P, Ducluzeau PH Davelu P, Andreelli F, Vallier P, Rion JP, Laville M & Vidal H (2002) Expression and regulation by insulin of low-density lipoprotein receptor-related protein mRNA in human skeletal muscle. Biochim Biophys Acta 1588, 226-231.
37. Hill MR, Young MD, McCurdy CM & Gimble JM (1997) Decreased expression, of murine PPARgamma in adipose tissue during endotoxemia. Endocrinology 138, 3073-3076.
38. Gayet C, Bailhache E, Dumon H, Mártin L, Siliart B & Nguyen P (2004) Insulin resistance and changes in plasma concentration of TNFalpha, IGF1, and NEFA in dogs during weight gain and obesity. J Anim Physiol Anim Nutr 88, 157-165.
39. De Vos P, Lefebvre AM, Miller SG, Querre-Millo M, Wong K, Saladin R, Hamann LG; Staels B, Briggs MR & Auwerx J (1996) Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma. J Clin Invest 98, 1004-1009.
40. Kallen CB & Lazar MA (1996) Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 373-L1 adipocytes. Proc Natl Acad Sci USA 93, 5793-5796.
41. Arita Y, Kihara S, Ouchi N, et al. (1999) Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257, 79-83.
42. Lapsys NM, Kriketos AD, Lim-Fraser M, Poynten AM, Lowy A, Furler SK Chisholm DJ & Cooney GJ (2000) Expression of genes involved in lipid metabolism correlate with peroxisome proliferator-activated receptor gamma expression in human skeletal muscle. J Clin Endocrinol Metab 85, 4293-4297.